MedPage Today on MSN
Long-Term Givinostat Data Reinforce Safety Profile in Duchenne Muscular Dystrophy
Givinostat is an oral histone deacetylase (HDAC) inhibitor approved by the FDA in 2024 to treat Duchenne patients ages 6 ...
7hon MSN
Sarepta’s stock plummets as disappointing trial data raise questions on DMD drug’s success
Shares of Sarepta Therapeutics Inc. plunged in extended trading Monday after the biotechnology company disclosed ...
Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...
Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...
Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting ...
From Corpus Christie, Texas, Jenn Mirabal, an MDA staff member and mother of a child living with Duchenne muscular dystrophy ...
Get Tuesday's top stock gainers and losers, plus market updates on Hims & Hers, Sarepta, crypto stocks, and Palantir.
Sarepta Therapeutics ( SRPT) shares fell after its late-stage trial for two gene therapies, AMONDYS 45 (casimersen) and VYONDYS 5 (golodirsen), aimed at treating Duchenne muscular dystrophy, did not ...
A San Diego community upgraded an adaptive van for Eddie Garcia, a boy with Duchenne Muscular Dystrophy, providing a motorized ramp to ease his mobility challenges.
Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...
His parents Stephen and Jenny have asked Sheffield Children's NHS Foundation Trust to approve the use of drug givinostat, ...
Researchers from Leiden University Medical Center and the University of Florida have found hundreds of blood proteins in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback